Stock Taper
SCREENER COMPARE ANY 2 STOCKS
TENX
TENAX THERAPEUTICS, INC.
NASDAQ
$1.94
▲ UP 8.99% (0.16)

KEY STATISTICS

Market Cap$51.33 M
52w High$19.40
52w Low$1.31
Dividend Yield—
Frequency—
P/E-1.31
Volume4.38M
Shares Out.26.53M

COMPANY

LEADERSHIP

Christopher T. Giordano
CHIEF EXECUTIVE
Christopher T. Giordano

COMPENSATION 2026

Salary$563,734
Stock Awards$0
Incentive Plan Pay$204,375
All Other Comp.$45,524
Total$8,079,633

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 4, 1994
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
15

PRICE TARGET

Target High$5.00
Target Low$4.00
Target Median$4.00
Target Consensus$4.40

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.—
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2024-01-03Reverse1:80
2023-01-05Reverse1:20
2018-02-26Reverse1:20
2013-05-28Reverse1:20
2013-05-13Reverse1:20
2009-11-09Reverse1:15

PRICE

$1.94 ▲ UP 8.99% (+$0.16)
OVERLAYS
$1.80$1.85$1.90$1.959:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.94

About Tenax Therapeutics, Inc.

https://www.tenaxthera.com ↗

Tenax Therapeutics, Inc. is a North Carolina-based specialty pharma developing and commercializing cardiovascular and pulmonary treatments, including levosimendan and imatinib, with several products in clinical trials.

INDUSTRY

Biotechnology

A PRODUCT TENAX THERAPEUTICS, INC. IS KNOWN FOR

TNX-103 (oral levosimendan)
TNX-103 (oral levosimendan)

TNX-103 is an oral levosimendan in Phase 3 trials for pulmonary hypertension related to heart failure with preserved ejection fraction, serving as the company's lead candidate for cardiopulmonary disease therapies.

COMPETITORS

COMPETITOR
GILD COMPARE
JNJ COMPARE
LQDA COMPARE
MRK COMPARE
UTHR COMPARE

Revenue by Products

IconPRODUCTQ4-2012
United States$2.87K

Revenue by Geography

MapREGIONQ4-2012
UNITED STATES$2.87K

ETFS HOLDING THIS STOCK

ETFS HOLDING
52
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 852.3K
IWM
0.00% · 644.4K
FESM
0.00% · 59.0K
ZPRR.DE
0.00% · 53.5K
DFMC
0.00% · 53.4K
SBIO
0.03% · 34.2K
XRS2.DE
0.00% · 21.3K
GSSC
0.00% · 17.4K
RSSL
0.00% · 11.9K
URTY
0.00% · 992
AVSC
0.00% · 338
RESM
0.00% · 46
SC0K.DE
0.00% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
50.12%
HOLDERS
86
TOP 12 OF 86 · RANKED BY POSITION SIZE
Price T Rowe Associates Inc /Md/
3.0M sh · $47.19M
Janus Henderson Group Plc
1.8M sh · $29.07M
Vr Adviser, LLC
1.7M sh · $26.79M
Perceptive Advisors LLC
1.4M sh · $23.15M
Ikarian Capital, LLC
1.0M sh · $16.27M
Stonepine Capital Management, LLC
975.2K sh · $15.59M
Logos Global Management LP
625.0K sh · $9.99M
Morgan Stanley
596.6K sh · $9.54M
Velan Capital Investment Management LP
583.3K sh · $9.33M
Adage Capital Partners Gp, L.L.C.
540.1K sh · $8.64M
Point72 Asset Management, L.P.
534.0K sh · $8.54M
Millennium Management LLC
533.9K sh · $8.54M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 187.7K shares
2026-09-02
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 179.1K shares
2026-09-01
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 403.6K shares
2026-08-31
★
10 PERCENT OWNER
ADAR1 Capital Management, LLC
Purchase · 202.1K shares
2026-08-20

MOST RECENT ANALYST GRADES

GRADE SUMMARY
NEUTRAL 2
OVERWEIGHT 2
BUY 1
IN LINE 1
MARKET PERFORM 1
7 GRADES IN THE LAST 12 MONTHS
Guggenheim NEUTRAL Chardan Capital NEUTRAL Canaccord Genuity BUY Evercore ISI Group IN LINE William Blair MARKET PERFORM Cantor Fitzgerald OVERWEIGHT Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
QTTB$12.05COMPARE
SABS$3.72COMPARE
ANTX$5.91COMPARE
NERV$4.56COMPARE
VRCA$5.35COMPARE
BOLD$2.85COMPARE
NXTC$7.88COMPARE
PLUR$1.44COMPARE